Who Optimizes SG&A Costs Better? Iovance Biotherapeutics, Inc. or Taro Pharmaceutical Industries Ltd.

SG&A Cost Management: Iovance vs. Taro

__timestampIovance Biotherapeutics, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014933577291733000
Thursday, January 1, 20151239000087644000
Friday, January 1, 20162560200092365000
Sunday, January 1, 20172126200085656000
Monday, January 1, 20182843000088196000
Tuesday, January 1, 20194084900089971000
Wednesday, January 1, 20206021000093413000
Friday, January 1, 20218366400091355000
Saturday, January 1, 2022104097000113676000
Sunday, January 1, 2023106916000198366000
Monday, January 1, 2024218935000
Loading chart...

In pursuit of knowledge

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Iovance Biotherapeutics, Inc. and Taro Pharmaceutical Industries Ltd. have taken different paths in this regard over the past decade.

From 2014 to 2023, Taro consistently maintained higher SG&A expenses, peaking at nearly $219 million in 2023. This represents a 150% increase from their 2014 expenses. In contrast, Iovance's SG&A costs grew more dramatically, surging over 1,000% from 2014 to 2023, reaching approximately $107 million.

While Taro's expenses show a steady upward trend, Iovance's rapid increase suggests aggressive expansion or investment in administrative capabilities. The data for 2024 is incomplete, but Taro's continued rise hints at further strategic investments. Understanding these trends can offer insights into each company's operational strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025